<DOC>
	<DOCNO>NCT02910076</DOCNO>
	<brief_summary>Antimalarials hydroxychloroquine ( HCQ ) , among old prescribe drug still use clinical practice . Relatively inexpensive well tolerate , drug recognize effective autoimmune disease rheumatoid arthritis ( RA ) systemic lupus erythematosus ( SLE ) . Interestingly , grow evidence beneficial impact cardiovascular risk , particularly diabetes . HCQ therapy improve balance patient unbalanced diabetes . This drug therapy may new therapeutic approach diabetes . There need good understand mechanisms responsible improvement metabolic response drug treatment . The investigator hypothesize treatment drug improve function beta cell ability secrete insulin response glucose . The investigator examine impact short-term therapy HCQ beta cell function healthy volunteer patient type 2 diabetes .</brief_summary>
	<brief_title>The Influence Plaquenil/Hydroxychloroquine ( HCQ ) Insulin Secretion</brief_title>
	<detailed_description />
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Two group participate study : Healthy volunteer Diabetes patient A . Healthy volunteer Age : 1840 Without acute disease day experiment . Signed informed consent Malignancy Steroids NSAID daily basis B. Diabetes patient Age : 2060 Diabetes type two Untreated metformin treatment Hypoglycemic medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>